
HealthEquity (HQY) Stock Forecast & Price Target
HealthEquity (HQY) Analyst Ratings
Bulls say
HealthEquity reported a 13% year-over-year increase in custodial revenue, contributing to an adjusted EBITDA margin of 44.0%, which improved by 466 basis points compared to the previous year. The company experienced a significant increase in cash flow from operations, rising 28.4% to $339.2 million for the fiscal year 2026, showcasing strong operational efficiency. Additionally, total revenue for Q3 2026 rose 7.2% to $322.2 million, bolstered by an increase in total HSA assets, which reached $36.5 billion, reflecting a 13.6% year-over-year growth and enhanced member engagement.
Bears say
HealthEquity's projected FY/27 revenue and adjusted EBITDA estimates have been slightly downgraded, indicating potential challenges in maintaining growth momentum, with expected revenue now at $1.410 billion and adjusted EBITDA at $623.3 million. The stock is currently trading at multiples that suggest overvaluation compared to its high-growth SaaS peers, presenting a concerning discrepancy as its shares have declined 13% year-to-date. The company faces a multitude of risks, including intense competition, evolving regulations in the healthcare sector, reliance on third-party suppliers, and potential operational challenges, which contribute to a negative outlook on its stock.
This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.
HealthEquity (HQY) Analyst Forecast & Price Prediction
Start investing in HealthEquity (HQY)
Order type
Buy in
Order amount
Est. shares
0 shares